A Decade after the Women’s Health Initiative—The Experts Do Agree
Leading medical societies devoted to the care of menopausal women agree that the decision to initiate hormone therapy should be for the indication of treatment of menopauserelated symptoms.
Cynthia A. Stuenkel, M.D., N.C.M.P., Margery L. S. Gass, M.D., N.C.M.P, J. E. Manson, M.D., Dr.P.H., N.C.M.P., Rogerio A. Lobo, M.D.; Lubna Pal, M.B.B.S., M.R.C.O.G., M.Sc., N.C.M.P., Robert W. Rebar, M.D., and Janet E. Hall, M.D.
Volume 98, Issue 2, Pages 313-314, August 2012
Systemic hormone therapy is an acceptable option for relatively young women (up to age 59 years or within 10 years of menopause) and for healthy women who are bothered by moderate to severe menopausal symptoms. Individualization is key in the decision to use hormone therapy. Consideration should be given to the woman’s quality-of-life priorities as well as her personal risk factors such as age, time since menopause, and her risk of blood clots, heart disease, stroke, and breast cancer.